Cyclofluidic Announces its Automated Chemical Synthesis-To-Screen Process for Drug Discovery
News Mar 16, 2011
Cyclofluidic‘s technology platform will significantly accelerate the drug discovery process, by giving researchers a platform to synthesize and test a greater range of potential new medicines in a considerably shorter time frame. It is envisaged that this new technology will radically transform drug discovery by improving both the efficiency and the overall cost to the industry.
Cyclofluidic has successfully demonstrated this fully integrated approach encompassing chemical synthesis of a pharmaceutically relevant molecule through to the generation of high quality target screening data. Cyclofluidic’s Chief Operating Officer David Parry commented “Achieving this scientific milestone represents a key stage in the evolution of Cyclofluidic.
We have demonstrated a fully integrated and automated approach to the generation of structure activity data which underpins modern drug discovery. The results illustrate the potential of the Cyclofluidic integrated approach to deliver next generation medicinal chemistry. I am delighted that we have been able to achieve such significant continued progress.”
“The interface between chemical synthesis and biological measurement is an exciting one, and tightening the connection between the two is a key challenge. This result shows that Cyclofluidic are making excellent progress in developing their internal capabilities” said David Klug, Professor of Chemical Biophysics and Head of the Imperial College Institute for Chemical Biology and chair of Cyclofluidic’s Scientific Advisory Board.
Currently, it takes between 12-15 years and a cost of up to US$1 billion to develop a new medicine. A key element of early stage pharmaceutical research is the synthesis and screening of new molecules as potential medicines against therapeutic targets. The research and development activities being undertaken within Cyclofluidic are expected to impact significantly on the timelines for the optimization of potential molecules.
By leveraging an organ-on-a-chip model and a bioreactor, four human gut metabolites have been identified that can help explain the enhanced sensitivity of the human colon towards enterohemorrhagic E. coli, which is responsible for more than 100,000 infections per year in the USA alone.READ MORE